Screener
Zevra Therapeutics, Inc. ZVRA Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
| Line item | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Discount and rebate liabilities | 3,457 | 6,359 |
| Operating lease liabilities | (234) | 746 |
| Other liabilities | 807 | (1,320) |
| Net cash provided by (used in) operating activities | 23,174 | (11,823) |
| Cash flows from investing activities: | ||
| Sale of future royalties, intellectual property, and other assets, net | 48,935 | — |
| Purchases of property and equipment | (252) | (312) |
| Purchases of investments | (80,836) | (157,712) |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s operating cash flow?
- Zevra Therapeutics, Inc. (ZVRA) reported operating cash flow of $17.03M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Zevra Therapeutics, Inc.'s operating cash flow increased by 573.0% year-over-year, from -$3.6M to $17.03M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s operating cash flow?
- Over 2 years (2022 to 2024), Zevra Therapeutics, Inc.'s operating cash flow has grown at a 92.9% compound annual growth rate (CAGR), from -$18.72M to -$69.67M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Zevra Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude